Citation Export
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, A. | - |
dc.contributor.author | Park, H. J. | - |
dc.contributor.author | Lee, E. S. | - |
dc.contributor.author | Park, S. B. | - |
dc.contributor.author | Kim, Y. K. | - |
dc.contributor.author | Choi, S. Y. | - |
dc.contributor.author | Ahn, S. | - |
dc.date.issued | 2020-04-01 | - |
dc.identifier.uri | https://dspace.ajou.ac.kr/dev/handle/2018.oak/31062 | - |
dc.description.abstract | AIM: To compare the diagnostic performance of the 2017 (v2017) and 2018 versions (v2018) of the Liver Imaging-Reporting and Data System (LI-RADS) for hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced magnetic resonance imaging (Gd-EOB-MRI) and to evaluate the effect in v2018. MATERIALS AND METHODS: Treatment-naive patients at high-risk for HCC who underwent Gd-EOB-MRI were included. The LI-RADS categories were assigned according to v2017 and v2018. The diagnostic performances were compared between v2017 and v2018 according to the size and combination of imaging features. RESULTS: A total of 117 patients with 137 observations were identified, including 89 HCCs; 76.2% (64/84) of observations with threshold growth were re-classified as subthreshold growth when using v2018 instead of v2017. The final categories changed in nine (14%) cases. For the combination of LR-5/LR-5V, there were no significant differences in sensitivity and specificity between the two versions (sensitivity, 64% versus 58.4%; specificity, 87.5% versus 85.4%; all p>0.05). For the combination of LR-4 and LR-5/5V, the diagnostic performance of v2018 was inferior to that of v2017 when considering only major features (accuracy, 86.1% versus 80.3%, respectively; p=0.013), particularly in observations measuring 10–20 mm, but was comparable after adding the ancillary features (accuracy, 86.9% versus 86.1%, respectively; p=1.00). CONCLUSION: In LI-RADS v2018, although a considerable number of observations re-classified subthreshold growth, changes in the assigned categories were insignificant; overall diagnostic performance was comparable to that of v2017, but v2018 might emphasise the value of ancillary features in combination with major features for determining the probability of HCC. | - |
dc.language.iso | eng | - |
dc.publisher | W.B. Saunders Ltd | - |
dc.subject.mesh | Aged | - |
dc.subject.mesh | Carcinoma, Hepatocellular | - |
dc.subject.mesh | Contrast Media | - |
dc.subject.mesh | Female | - |
dc.subject.mesh | Gadolinium DTPA | - |
dc.subject.mesh | Humans | - |
dc.subject.mesh | Liver Neoplasms | - |
dc.subject.mesh | Magnetic Resonance Imaging | - |
dc.subject.mesh | Male | - |
dc.subject.mesh | Middle Aged | - |
dc.subject.mesh | Retrospective Studies | - |
dc.subject.mesh | Sensitivity and Specificity | - |
dc.title | Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI | - |
dc.type | Article | - |
dc.citation.endPage | 319.e9 | - |
dc.citation.startPage | 319.e1 | - |
dc.citation.title | Clinical Radiology | - |
dc.citation.volume | 75 | - |
dc.identifier.bibliographicCitation | Clinical Radiology, Vol.75, pp.319.e1-319.e9 | - |
dc.identifier.doi | 10.1016/j.crad.2019.11.004 | - |
dc.identifier.pmid | 31858990 | - |
dc.identifier.scopusid | 2-s2.0-85076612500 | - |
dc.identifier.url | http://www.elsevier.com/inca/publications/store/6/2/3/0/1/9/index.htt | - |
dc.description.isoa | false | - |
dc.subject.subarea | Radiology, Nuclear Medicine and Imaging | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.